Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).


Journal

Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017

Informations de publication

Date de publication:
02 2021
Historique:
received: 21 10 2020
accepted: 06 02 2021
entrez: 20 2 2021
pubmed: 21 2 2021
medline: 24 11 2021
Statut: epublish

Résumé

Diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) is usually straightforward, involving clinical, immunophenotypic (Matutes score), and (immuno)genetic analyses (to refine patient prognosis for treatment). CLL cases with atypical presentation (e.g., Matutes ≤ 3) are also encountered, and for these diseases, biology and prognostic impact are less clear. Here we report the genomic characterization of a case of atypical B-CLL in a 70-yr-old male patient; B-CLL cells showed a Matutes score of 3, chromosomal translocation t(14;18)(q32;q21) (

Identifiants

pubmed: 33608382
pii: mcs.a005934
doi: 10.1101/mcs.a005934
pmc: PMC7903887
pii:
doi:

Substances chimiques

BCL2 protein, human 0
Cell Cycle Proteins 0
Homeodomain Proteins 0
LRIF1 protein, human 0
NKX2-3 protein, human 0
NOTCH1 protein, human 0
PAX5 Transcription Factor 0
PAX5 protein, human 0
Proto-Oncogene Proteins c-bcl-2 0
Receptor, Notch1 0
TP53 protein, human 0
Transcription Factors 0
Tumor Suppressor Protein p53 0
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021 Burlet et al.; Published by Cold Spring Harbor Laboratory Press.

Références

Am J Blood Res. 2011;1(1):13-21
pubmed: 22432063
Leukemia. 2009 Nov;23(11):1989-98
pubmed: 19587702
Nat Immunol. 2007 May;8(5):463-70
pubmed: 17440452
Nat Commun. 2016 Jun 14;7:11889
pubmed: 27297662
J Proteome Res. 2017 Sep 1;16(9):3433-3442
pubmed: 28704058
Hum Mutat. 2019 Aug;40(8):1030-1038
pubmed: 31116477
Neurology. 2020 Jun 9;94(23):e2441-e2447
pubmed: 32467133
J Cell Biochem. 2007 Nov 1;102(4):1021-35
pubmed: 17455211
Blood. 2020 Oct 09;:
pubmed: 33036026
Genome Res. 2005 Jul;15(7):901-13
pubmed: 15965027
Cancer Discov. 2019 Mar;9(3):329-341
pubmed: 30770389
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Blood. 2010 Apr 15;115(15):3089-97
pubmed: 20160164
Haematologica. 2019 Mar;104(3):576-586
pubmed: 30262568
Am J Hematol. 2019 Mar;94(3):338-345
pubmed: 30575108
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Blood. 2015 Jun 4;125(23):3609-17
pubmed: 25855603
Cancer Discov. 2014 Sep;4(9):1088-101
pubmed: 24920063
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Nat Struct Mol Biol. 2013 May;20(5):566-73
pubmed: 23542155
Cancers (Basel). 2019 Nov 26;11(12):
pubmed: 31779217
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Mol Cell Biol. 2015 Dec;35(23):4053-68
pubmed: 26391951
Nat Commun. 2013;4:2848
pubmed: 24270157
Blood. 2016 Jun 16;127(24):3040-53
pubmed: 27060168
Int J Cancer. 2020 Nov 15;147(10):2780-2792
pubmed: 32720348
Nature. 2007 Apr 12;446(7137):758-64
pubmed: 17344859
Front Immunol. 2014 Apr 11;5:156
pubmed: 24782862

Auteurs

Bénédicte Burlet (B)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Unit for innovation in genetics and epigenetics in oncology, Dijon University Hospital, 21079 Dijon, France.

Selim Ramla (S)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Department of Pathology, Dijon University Hospital, 21079 Dijon, France.

Cyril Fournier (C)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Unit for innovation in genetics and epigenetics in oncology, Dijon University Hospital, 21079 Dijon, France.

Maria Jimena Abrey-Recalde (MJ)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.

Camille Sauter (C)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.

Marie-Lorraine Chrétien (ML)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Hematology Laboratory, Dijon University Hospital, 21079 Dijon, France.

Cédric Rossi (C)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Department of Clinical Hematology, Dijon University Hospital, 21079 Dijon, France.

Yannis Duffourd (Y)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.

Sylviane Ragot (S)

Unit for innovation in genetics and epigenetics in oncology, Dijon University Hospital, 21079 Dijon, France.

Céline Buriller (C)

Genetics Laboratory, Dijon University Hospital, 21079 Dijon, France.

Benjamin Tournier (B)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Unit for innovation in genetics and epigenetics in oncology, Dijon University Hospital, 21079 Dijon, France.
Department of Pathology, Dijon University Hospital, 21079 Dijon, France.

Caroline Chapusot (C)

Department of Pathology, Dijon University Hospital, 21079 Dijon, France.

Nathalie Nadal (N)

Genetics Laboratory, Dijon University Hospital, 21079 Dijon, France.

Jessica Racine (J)

Hematology Laboratory, Dijon University Hospital, 21079 Dijon, France.

Julien Guy (J)

Hematology Laboratory, Dijon University Hospital, 21079 Dijon, France.

François Bailly (F)

Hematology Laboratory, Dijon University Hospital, 21079 Dijon, France.

Laurent Martin (L)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Department of Pathology, Dijon University Hospital, 21079 Dijon, France.

Olivier Casasnovas (O)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Department of Clinical Hematology, Dijon University Hospital, 21079 Dijon, France.

Jean-Noël Bastie (JN)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Department of Clinical Hematology, Dijon University Hospital, 21079 Dijon, France.

Denis Caillot (D)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Department of Clinical Hematology, Dijon University Hospital, 21079 Dijon, France.

Juliette Albuisson (J)

Oncogenetics laboratory, Centre George François Leclerc, 21079 Dijon, France.

Cyril Broccardo (C)

Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université de Toulouse III - Paul Sabatier, 31037 Toulouse, France.

Catherine Thieblemont (C)

Department of Hemato-oncology, Hôpital Saint-Louis, AP-HP, 75010 Paris, France.
Université de Paris, NF-kappaB, Différenciation et Cancer, 75006 Paris, France.

Laurent Delva (L)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.

Marc Maynadié (M)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Hematology Laboratory, Dijon University Hospital, 21079 Dijon, France.
Registre des hémopathies malignes de Côte d'Or, University of Burgundy, Faculty of Medicine, 21079 Dijon, France.

Romain Aucagne (R)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Unit for innovation in genetics and epigenetics in oncology, Dijon University Hospital, 21079 Dijon, France.

Mary B Callanan (MB)

University of Burgundy-ISITE-BFC-Institut national de la santé et de la recherche médicale (Inserm) UMR1231, Faculty of Medicine, 21079 Dijon, France.
Unit for innovation in genetics and epigenetics in oncology, Dijon University Hospital, 21079 Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH